New therapies are needed for patients with severe persistent asthma who cannot achieve control with current therapy of inhaled corticosteroids and long-acting b 2 -agonists. Bronchial thermoplasty is a novel intervention for asthma that delivers controlled thermal energy to the airway wall during a series of bronchoscopies, resulting in a prolonged reduction in airway smooth muscle mass. We review the method of performing bronchial thermoplasty with the Alair System, how to appropriately select and manage patients undergoing bronchial thermoplasty, and the clinical experience to date with this treatment. Randomized, controlled clinical trials with bronchial thermoplasty in subjects with severe asthma have resulted in improvements in overall asthma control as demonstrated by significant improvement in quality of life, asthma symptoms, severe exacerbations requiring corticosteroids, days lost from work/school/other daily activities due to asthma, and healthcare utilization.
Asthma: the disease Asthma is characterized by chronic inflammation of the airways, airway wall edema, bronchial hyperresponsiveness and remodeling of the airways [Cohen et al. 2007; Bergeron and Boulet, 2006; Bousquet et al. 2000; Castro et al. 1998; Carroll et al. 1993] ; chronically, this remodeling includes increased airway smooth muscle mass. Each of these factors, either alone or in combination, can result in recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These episodes are usually associated with varying degrees of airflow obstruction that is often reversible either spontaneously or with treatment. The role of environmental factors on proinflammatory mediators, and the local microenvironment of the airways continue to be a major focus of research in understanding the pathogenesis of asthma [Gilmour et al. 2006; Kicic et al. 2006; Vercelli, 2004; Weiss et al. 2001] . Although inflammation of the airways is a hallmark of asthma, it is contraction of the excess airway smooth muscle that is the main cause of airway constriction that leads to difficulty in breathing during asthma attacks.
Impact of severe asthma
Even as progress is made towards understanding the pathogenesis and pathophysiology of the disease, asthma continues to be a major health concern for over 22 million people in the United States [Center for Disease Control, 2006 ]. Approximately 1520% of these patients are characterized as having severe, persistent asthma as defined by the presence of asthma symptoms despite treatment with current, state-of-the-art medications [Moore et al. 2007 ]. Poorly controlled asthma imposes a significant disease burden on the patient [Fuhlbrigge et al. 2002] leading to decreased quality of life, increased healthcare utilization and economic burden [Schatz et al. 2008; Antonicelli et al. 2004; Godard et al. 2002; Vollmer et al. 2002; Serra-Battles et al. 1998 ]. Currently available therapeutic interventions (Table 1) include long-term controller medications, used to achieve and maintain control of persistent asthma, and quick-relief medications used to treat acute symptoms and exacerbations. Long-term controller medications for severe persistent asthma include high-dose inhaled corticosteroids (ICS), long-acting b 2 -agonists (LABA), and, in a subset of patients, chronic oral corticosteroids (OCS). Although the current treatment of severe asthma has improved the level of asthma control, there remains a significant proportion of patients who do not achieve control and have recurrent exacerbations requiring systemic corticosteroids [Moore et al. 2007 ].
Chronic asthma is associated with an abnormally increased mass of airway smooth muscle [Bergeron and Boulet, 2006; Carroll et al. 1993 ]. This muscle constricts in response to the various asthma triggers, resulting in bronchospasm and severely restricted airflow. A physical reduction of this excess mass of smooth muscle that is present in the wall of airways of patients with asthma would have a number of theoretical benefits ]. In addition to reducing one element of airway remodeling, a reduction in the amount of muscle present would diminish the potential for bronchoconstriction. The benefits of such an intervention might include fewer symptoms of airflow obstruction, less-severe airway narrowing during exacerbation, and less variability of the disease. Bronchial thermoplasty, a novel device-based approach to treat severe persistent asthma, was developed to reduce this abnormal increase in airway smooth muscle mass.
Bronchial thermoplasty with the Alair System
The Alair Õ System (Asthmatx Inc., Sunnyvale, CA) is the first device designed to use radiofrequency (RF) or thermal energy to selectively reduce the amount of excess airway smooth muscle in airways distal to the main stem bronchi down to 3 mm in diameter. The following sections describe the Alair System, the method of performing bronchial thermoplasty delivered by the Alair System, and the clinical experience to date.
The Alair System comprises the Alair RF Catheter and the Alair RF Controller (Figure 1 ). The Alair catheter is deployed under direct vision through the working channel (2.0 mm) of a RF or high-frequency compatible flexible bronchoscope, ideally with a 4.95.2 mm outer diameter. The electrode array is expanded to contact the airway walls and then activated to deliver RF (A) (B) Figure 1 . Alair Bronchial Thermoplasty System. Alair Radiofrequency (RF) Controller (A) provides controlled delivery of RF energy to the Alair Catheter. Energy from the Controller is delivered to the Catheter through the electrical cable attached to the proximal end of the catheter handle. The Controller delivers low-power, temperature-controlled RF energy to the airway at a predetermined temperature setting (65 C) for a predetermined time period (maximum 10 seconds). Actual power delivered (120 J) is automatically modulated by the Controller based on temperature control algorithms. The Controller incorporates hardware and software features that limit current, voltage, power, energy, time, and temperature during each application of RF energy. Alair RF Catheter ((A) and (B)) is a single use, flexible catheter with an expandable electrode array attached at one end, and a deployment handle on then other. (B) The expandable catheter and proximal markings on the catheter spaced 5 mm apart. A footswitch connected to the Alair RF Controller is used to activate the Controller to deliver a single pulse of energy. A standard gel-type patient return electrode also connected to the Controller is needed to complete the electrical conductance path.
Therapeutic Advances in Respiratory Disease 4 (2) electrical energy over the 5 mm length of the exposed electrode. The transfer of RF energy from the electrode to the tissue results in resistance that causes the electrical energy to be converted to thermal energy. The Controller delivers the correct intensity and duration of energy that results in a reduction in the amount of airway smooth muscle, while limiting/minimizing collateral damage to other airway supporting structures [Danek et al. 2004] . Figure 2 shows representative histological sections of an untreated and treated canine airway (3 years posttreatment) demonstrating the reduction of airway smooth muscle.
Procedure technique
Currently, bronchial thermoplasty treatment is performed during three bronchoscopy sessions, each separated by about 3 weeks. This divided treatment minimizes the risk of inducing an asthma exacerbation that might occur if the entire tracheobronchial tree was accessed and treated during a single session and limits the time of each bronchoscopy to about an hour. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. To date the right middle lobe has not been treated because of theoretical concerns of right middle lobe syndrome stemming from the long and narrow airway typically leading to the right middle lobe Gudmundsson and Gross, 1996] . Hence, no experience exists in treating the right middle lobe with bronchial thermoplasty at the present time. During each subsequent session, previously treated airways are evaluated visually by bronchoscopy to ensure adequate healing of previously treated segments before proceeding with further treatment. If previously treated areas have not healed, consideration should be given to postponing treatment [Mayse et al. 2007] . Following this inspection, the bronchoscope is navigated to the region of the lung that is to be treated and the bronchoscopist plans the order in which the airway segments are to be accessed and treated. The bronchoscopist then navigates to the most distal region of the first airway to be treated, positioning the bronchoscope with the targeted treatment site in clear bronchoscopic view. The catheter is then introduced into the working channel of the bronchoscope and advanced until the distal end is in bronchoscopic view. Once at the targeted region, the electrode array ( Figure 1) is expanded until the four electrode wires firmly contact the airway wall, being careful not to overexpand the electrodes as this may result in distortion of the electrode array. Proper contact of the electrodes with the airway wall should be confirmed visually.
With the electrode array properly positioned and expanded, the bronchoscopist initiates energy delivery by pressing and releasing the controller footswitch. The controller automatically delivers energy according to preset treatment parameters programmed into the controller. The bronchoscopist should continue to apply contiguous and not overlapping activations throughout accessible airways distal to the main stem bronchi down to 3 mm in diameter. The atraumatic catheter distal tip diameter is 1.5 mm and can be used as a reference for sizing the airway under direct visualization. The electrode array is partially collapsed immediately following each activation and repositioned proximally about 5 mm, adjacent to and not overlapping the previous activation site. The catheter's distal marker bands, which are visible through the bronchoscope, are spaced 5 mm apart to assist with contiguous placement (Figure 1 ). This process is repeated along the entire length of the targeted airways. The electrode array position should be referenced to anatomical landmarks because of the potential for relative motion between the bronchoscope, catheter, and airways.
A systematic approach from distal to proximal, working methodically from airway to airway across the region of lung being treated is recommended to ensure that all accessible airways are carefully identified and treated once and only once. The use of a 'map' of the airways to plan and track the progression of the treatment for each session is recommended ( Figure 3) .
Key elements for the successful administration of bronchial thermoplasty include careful selection of the patients to be treated, patient preparation for the procedure, patient management during the bronchoscopy, and postprocedure care. Each of these elements has been comprehensively described by Mayse et al. [2007] and is discussed here briefly.
Patient selection
Patients should be selected for bronchial thermoplasty by a medical team consisting of an asthma specialist closely associated with an experienced bronchoscopist. In some cases, the same A detailed medical history and appropriate medical evaluations are important to inform and determine the patient's suitability to undergo this procedure.
Patient preparation
Critical elements of patient preparation include the prophylactic administration of prednisone or equivalent at a dosage of 50 mg/day for the 3 days prior to the procedure, the day of the procedure, and the day after the procedure in order to minimize postprocedure inflammation of the airways [Castro et al. 2010; Pavord et al. 2007 ]. With each procedure, the asthma specialist and/or bronchoscopist should ensure that patients:
. do not present with cold or flu symptoms the day before or day of the procedure; . are kept on observation for an appropriate period of time after each procedure; and . are discharged when their lung function is acceptable (for example, postbronchodilator Forced Expiratory Volume in 1 Second (FEV 1 ) ! 80% of pre-procedure value) and all sedation related effects have subsided.
Patient management
Bronchial thermoplasty can only be performed effectively when a patient is adequately medicated to provide anxiolysis and analgesia, thereby ensuring patient comfort and reducing excessive patient movement. Reducing airway secretions using an anticholinergic medication (e.g. glycopyrrolate) prior to the procedure is also important to the procedure's success. Good topical anesthesia of the airway with an appropriate level of sedation (moderate sedation) not only facilitates the procedure, but will also increase patient comfort. A positive experience during the initial bronchoscopy session should increase the patient's willingness to complete the second and third bronchoscopy procedures and attain the benefits of a full bronchial thermoplasty treatment.
Clinical evaluation of bronchial thermoplasty A total of four clinical studies in patients with asthma of differing severity have contributed to the clinical experience with bronchial thermoplasty to date. The key inclusion criteria for these studies are shown in Table 2 , and each of the studies is summarized below.
Feasibility study in patients with mild to moderate asthma The first application of bronchial thermoplasty in patients with asthma was in 16 patients with mild to moderate asthma. The study conducted at two centers was a single-arm study designed to evaluate the safety of the procedure. Clinical data on the first 2 years of follow up supported safety and provided the basis for further clinical study ]. The key findings of this study were:
. No device malfunctions or safety concerns related to the device. . Side effects were transient and similar to those commonly observed after bronchoscopy in patients with asthma. . The most common side effects observed were cough, dyspnea, and wheeze. . No hospitalizations or life-threatening adverse events related to asthma in the 2-year period. . Pulmonary function (relatively high in this group) was maintained. . All subjects were discharged the same day of treatment (within 6 hours of the procedure). . CT scans at 1 and 2 years confirmed no negative long-term effects related to the procedure.
In addition this study showed early effectiveness with improved peak flow rates, increased symptom-free days at 3 months following the procedure, and diminished bronchial hyperresponsiveness at 3 and 12 months following the procedure. A satisfactory long-term safety profile of bronchial thermoplasty out to 5 years (based on the absence of any qualitative [CT scans], functional [spirometry], or clinical complications) has been reported [Cox et al. 2009 ].
Patient satisfaction with the treatment was acceptable as all patients indicated that they would 'probably' or 'definitely' undergo the procedure again, if they had to do it all over again, and would 'probably' or 'definitely' recommend it to a friend or family member [Wilson et al. 2006 ]. Subjects reported an increase in ability to carry out activities, increase in tolerance to allergens, and increased tolerance for physical exertion [Wilson et al. 2006 ].
Asthma Interventional Research Trial in patients with moderate to severe asthma The Asthma Intervention Research Trial (AIR) was a randomized controlled trial in 11 centers worldwide to evaluate the effectiveness and safety of bronchial thermoplasty in subjects with moderate to severe asthma ]. All subjects (56 in the bronchial thermoplasty group and 56 in the control group) were on standard asthma care, requiring ICS and LABA to maintain asthma control, and demonstrated the need for their LABA at baseline by worsening of their asthma control upon LABA withdrawal. Treated subjects received bronchial thermoplasty in addition to standard care (ICS þ LABA), while control subjects received standard care only.
The primary outcome of the study was the frequency of mild exacerbations. Figure 4 shows the change from baseline for both the mild and severe exacerbation rates while subjects are on ICS alone. Bronchial thermoplasty treated subjects had a significantly greater reduction in the mild exacerbation rates at 3 months and 12 months compared with the control group. The greater reduction in the severe exacerbation rates in the bronchial thermoplasty group compared with the control group did not achieve statistical significance. Other assessments on ICS alone included patient-centered outcomes, such as symptom score (scale of 018 with lower numbers indicating fewer and less-severe symptoms), symptom-free days, rescue medication use, asthma quality of life (scale of 1 to 7 with higher numbers indicating better quality of life), asthma control (scale of 0 to 6 with lower numbers indicating better asthma control), and lung function outcomes, such as FEV 1 and peak flow rates. The data for these endpoints are shown graphically in Figure 5 as change from baseline at 3, 6, and 12 months.
Compared with a control group that did not receive the outpatient procedure, subjects treated with bronchial thermoplasty, on average after 1 year:
. experienced 10 fewer asthma attacks (mild exacerbations) per year; . needed 400 fewer puffs of their rescue medication (two less canisters/year); . enjoyed 86 more days completely free of symptoms; . had significant improvements in asthma control and quality of life.
As had been anticipated, performing bronchial thermoplasty in patients with more severe disease caused a temporary increase of airway symptoms. These were usually evident on the day of the procedure and on two occasions were severe enough to require hospital admission. However, during the posttreatment period, which begins 6 weeks after the third bronchoscopy, there were no treatment-related adverse events out to 52 weeks. The key safety outcomes were summarized as follows:
. Most common respiratory-related adverse events during treatment period (first bronchoscopy through 6 weeks after the last bronchoscopy) were: dyspnea, wheeze, cough, chest discomfort, night awakenings, and productive cough. The majority of these adverse events occurred within 1 day of the procedure, and resolved an average of 7 days after the onset of the event. The bronchial thermoplasty group had more hospitalizations for adverse respiratory events during the treatment period (four subjects required six hospitalizations: four for asthma, one for partial left lower lobe collapse, one for pleurisy) versus two control subjects each requiring one hospitalization. . During the posttreatment period (between 6 and 52 weeks after treatment) the rate of hospitalization for respiratory adverse events was low and did not differ significantly between the groups. Research in Severe Asthma Trial in patients with severe refractory asthma The Research in Severe Asthma (RISA) Trial was a randomized, controlled clinical trial in eight centers worldwide designed to study the safety and effectiveness of bronchial thermoplasty in symptomatic, severe, persistent asthma subjects [Pavord et al. 2007 ]. The 32 subjects studied had to be symptomatic despite treatment with high-dose asthma controller medications (>750 mg/day of fluticasone or equivalent, LABA, and could also be taking up to 30 mg oral prednisone/day). Fifteen subjects in the treated group received bronchial thermoplasty in addition to these standard medications and 17 received usual care. Both groups remained on baseline medications through 22 weeks, before attempting to wean oral and ICS in a prespecified 14-week (steroid wean) period. Subjects were then followed an additional 4 months (through a total of 1 year follow up from treatment) to determine stability of any change in medications that resulted from the steroid wean.
The bronchial thermoplasty group showed major improvement in various measures of asthma including FEV 1 , quality of life, asthma control, and use of rescue medications. In the steroid Mean values for changes from baseline in each parameter are shown for all subjects for whom data were available at the given time points.
stable phase, clinically and statistically significant changes compared with control were observed in:
. use of rescue medication (25 fewer puffs/7 days); . FEV 1 , percentage predicted (15.8% improvement in lung function); . quality of life (þ1.1 in Asthma Quality of Life score, on scale of 1 to 7 with higher numbers indicating better quality of life); . asthma control (À0.9 in ACQ score, on scale of 0 to 6 with lower numbers indicating better asthma control).
In the steroid wean phase, three subjects in the control group did not attempt steroid reduction due to unstable asthma. All subjects in the bronchial thermoplasty group were able to initiate steroid reduction.
In the reduced steroid extension phase (weeks 3652), four of eight bronchial thermoplasty subjects were able to completely wean off OCS and stay off through 52 weeks, compared with one of seven control subjects. A greater overall reduction in OCS dose was observed in the bronchial thermoplasty group compared with the control group at 52 weeks (63.5% reduction versus 26.2%, p ¼ 0.12). Despite this difference in corticosteroid use, statistically significant improvements over baseline for bronchial thermoplasty compared with control were observed in rescue medication use, and quality of life and asthma control scores 4 months after the steroid wean phase was complete.
As expected in this severe refractory asthma group undergoing bronchoscopy, there was a temporary increase in the severity of respiratory adverse events in the bronchial thermoplasty group shortly after the procedure compared with controls (who did not undergo bronchoscopy); 5 hospital admissions occurred within 1 week following a total of 45 bronchial thermoplasty procedures. The key safety outcomes were summarized as follows:
. The most common respiratory adverse events during the treatment period were: wheeze, cough, chest discomfort, dyspnea, productive cough, and discolored sputum. A majority of these adverse events occurred within 1 day of the procedure, and resolved an average of 7 days after the onset of the event.
. There was a higher rate of hospitalization in the treatment group during the treatment period (seven hospitalizations in four subjects compared with no hospitalizations in the control group). However subsequently during the posttreatment period, the treatment group had a similar number of hospitalizations compared with the control group, and a lower number of hospitalizations compared with baseline.
Asthma Intervention Research 2 Trial in patients with severe persistent asthma The Asthma Intervention Research 2 (AIR2) Trial was a multicenter, randomized, doubleblind, sham-controlled trial that demonstrated effectiveness and safety of bronchial thermoplasty with the Alair System in a population of subjects with severe asthma who were still symptomatic despite being managed on conventional therapy of ICS (doses greater than 1000 mg per day beclomethasone or equivalent) and LABA (doses of at least 100 mg per day salmeterol or equivalent) [Castro et al. 2010] .
A total of 297 subjects were randomized (196 in the bronchial thermoplasty group and 101 in the sham group) on the highest level of care (e.g. Advair Õ 500 equivalent) to undergo three bronchoscopy procedures; each procedure separated by 3 weeks. Two-thirds of subjects received bronchial thermoplasty and one-third received a sham procedure. The treatment was administered by an unblinded bronchoscopy team. All follow-up and assessment visits were conducted by a blinded assessment team. Thus, neither the subject nor the physician assessor was aware of the individual treatment assignment. Sham procedures were performed using an RF controller that provided audio and visual cues that mimicked the active controller, but did not deliver RF energy through the catheter.
All endpoints were analyzed using Bayesian statistics (an axiomatic approach that provides the probability of hypotheses conditional on observed data rather than the traditional approach of calculating the probability of data conditional on hypotheses). The posterior probability is a central measure of uncertainty within the Bayesian approach and is used to quantify the strength of the evidence regarding hypotheses, such as the probability of superiority, which is used in this study.
The primary effectiveness endpoint was the difference between study groups in the change in AQLQ score from baseline and the average of 6-, 9-, and 12-month follow-up visits (6, 9, and 12 months after the last bronchoscopy session). The bronchial thermoplasty group had improved quality of life compared with the sham group as demonstrated by the observed difference between the bronchial thermoplasty and sham groups in the average change in AQLQ score from baseline at the 6-, 9-, and 12-month follow-up visits. For the intention to treat (ITT) population, the difference between the groups had a posterior probability of superiority of 96.0%, and for the per protocol (PP) population, the difference between the groups had a posterior probability of superiority of 97.9%, demonstrating an improvement in the AQLQ score in the bronchial thermoplasty group compared with the sham group.
The AQLQ data were used to categorize the proportion of subjects in each group that achieved an improvement in the integrated AQLQ score of !0.5, or a minimal important difference (MID) [Juniper et al. 1994 ]. This analysis was not prespecified in the protocol, and is provided to allow perspective on within-subject changes. For both the ITT and PP populations, a greater proportion of subjects in the Alair group (ITT: 79%; PP: 81%) compared with the sham group (ITT: 64%; PP: 63%) achieved an improvement in AQLQ score of !0.5 (posterior probability of superiority for ITT population [bronchial thermoplasty sham] 99.6%; posterior probability of superiority for PP population [bronchial thermoplasty sham] >99.9%).
Although the clinical study was powered only for the primary effectiveness endpoint, several effectiveness endpoints and safety endpoints that can be considered effectiveness endpoints demonstrated clinically meaningful and statistically significant differences in favor of the bronchial thermoplasty group compared with the sham group.
Severe exacerbation rate and proportion of subjects experiencing steroid exacerbations were reduced. There was a 32% reduction in rate of severe exacerbations requiring systemic corticosteroids in the bronchial thermoplasty group compared with the sham group (0.48 versus 0.70 severe exacerbations per subject per year in the bronchial thermoplasty and sham groups during the posttreatment period, respectively (posterior probability of superiority of 95.5% [95% confidence interval (CI) {sham bronchial thermoplasty}: À0.031, 0.520]).
During the posttreatment period, there was a 34% reduction in the proportion of subjects experiencing steroid exacerbations (26.3% in the bronchial thermoplasty group and 39.8% in the sham group; posterior probability of superiority of 99.0% [95% CI {sham bronchial ther-moplasty}: 2.1%, 25.1%]) ( Figure 6 ).
Days lost from work, school, or other daily activities due to asthma symptoms were reduced. During the posttreatment period, there was a 66% reduction in days lost from work, school, or other daily activities due to asthma in the bronchial thermoplasty group compared with the sham group (1.3 versus 3.9 days/ year/subject; posterior probability of superiority 99.3% [95% CI {sham bronchial thermo-plasty}: 0.425, 6.397]).
Safety endpoints that demonstrated effectiveness. During longer-term follow up (>6 weeks after the last bronchial thermoplasty treatment out to 1 year), there was a significant reduction in multiple symptoms of asthma (posterior probability of superiority of 96.0%) ( Figure 6 ), emergency department visits for respiratory symptoms (posterior probability of superiority of 99.9%), and hospitalizations for respiratory symptoms (Figure 7 ).
There was also a significant reduction in the proportion of subjects having multiple symptoms of asthma (posterior probability of superiority of 99.6%: [95% CI {sham bronchial thermo-plasty}: 4.0%, 27.3%]), and in the proportion of subjects having emergency department visits for respiratory symptoms in the bronchial thermoplasty group (3.7% in the bronchial thermoplasty group compared with 15.3% in the sham group), posterior probability of superiority of >99.9% (95% CI [sham bronchial thermoplasty]: 4.6%, 19.7%).
No deterioration in FEV 1 over time. No deterioration in FEV 1 was observed in either the bronchial thermoplasty or sham group throughout the 12-month follow-up.
Other secondary endpoints. All other secondary endpoints, including percentage of symptom-free days, total symptom score, rescue medication use, ACQ and morning Peak Expiratory Flow (am PEF), showed improvements in the bronchial thermoplasty group over the sham group, although the differences between the groups were not statistically significant.
Key findings for bronchial thermoplasty treated subjects versus the sham group in the AIR2 Trial were:
. improved asthma quality of life;
. reduction in rate of severe exacerbations;
. reduction in emergency department visits for respiratory symptoms;
. reduction in days lost from work/school/other daily activities due to asthma; . reduction in percentage of subjects with multiple symptoms of asthma.
Safety results. A total of 850 bronchoscopy procedures were performed in 288 subjects in the AIR2 Trial. Of these 558 were bronchial thermoplasty treatment bronchoscopy procedures performed in 190 subjects and 292 sham bronchoscopy procedures performed in 98 subjects. There were no incidences of pneumothorax, intubation, mechanical ventilation, cardiac arrhythmias, or death as a result of bronchial thermoplasty treatment. There was no evidence of airway stenosis or focal narrowing based on observations during bronchoscopy.
The key safety findings from the AIR2 Trial include the following:
. Transient increase in respiratory adverse events peri-procedure. During the treatment period (from first treatment through 6 weeks after the third treatment), there was a significant transient increase in respiratory adverse events, including asthma (multiple symptoms), upper respiratory tract infection, atelectasis, lower respiratory tract infection, wheezing, hemoptysis, and anxiety in the bronchial thermoplasty group compared with the sham group. Respiratory adverse events were experienced by 84.7% of subjects in the bronchial thermoplasty group compared with 75.5% of subjects in the sham groups. The median time to onset following bronchoscopy for respiratory adverse events was 1.0 day for the bronchial thermoplasty group (average within 5.9 days) and 1.0 day for the sham group (average within 7.2 days). During the treatment period, 16 subjects in the bronchial thermoplasty group required 19 hospitalizations for respiratory symptoms (most common cause was worsening of asthma: 12 in 10 subjects) compared with two subjects (2.0%) in the sham group requiring two hospitalizations (both worsening of asthma). Ten of the 19 hospitalizations in the bronchial thermoplasty group occurred on the day of the procedure. All adverse events were resolved with standard therapy.
. High-resolution CT (HRCT) scans. Blinded comparison of HRCT scans at baseline and 12-month follow-up from 100 bronchial thermoplasty and 50 sham subjects revealed no structural changes in the lung. In addition, there was no evidence of bronchial dilation, bronchiectasis, bronchiolitis obliterans, or pulmonary emphysema in any of the bronchial thermoplasty treated subjects at 1-year posttreatment. A difference was seen in bronchial wall thickening without gas trapping which occurred only in the sham group (4%).
Long-term safety of bronchial thermoplasty
The long-term safety of treatment with the Alair System beyond one year has been evaluated in the first three clinical trials in patients with asthma. Long-term follow-up data are available out to 5 years from the Feasibility Study, out to 3 years from the AIR Extension Study and out to 3 years from the RISA Extension Study [Cox et al. 2009 ]. In all, including the 1 year follow up from the AIR2 Trial, greater than 446 patient-year follow-up data have been accumulated. Each of these longer-term studies demonstrates consistency over time in the safety profile for the bronchial thermoplasty treated patients including respiratory adverse events and healthcare utilization. 
Concluding comments
Bronchial thermoplasty delivered by the Alair System provides a novel, procedure-based treatment for severe asthma that is refractory to conventional therapy. If the Alair System is approved by the US Food and Drug Administration, we expect it to be indicated for treating patients 18 years or older with severe persistent asthma that is uncontrolled with ICS and LABA. Pulmonologists, allergists, asthma experts, and respiratory therapists should become familiar with the use of bronchial thermoplasty and appropriate selection and management of patients for this procedure. Randomized, controlled clinical trials to date with bronchial thermoplasty have demonstrated significant improvement in outcomes that are important to our patients: quality of life, asthma symptoms, severe exacerbations requiring corticosteroids, days lost from work/school/other daily activities due to asthma, and healthcare utilization. Bronchial thermoplasty will be used in conjunction with the current standard of asthma care. However, unlike the currently used drug therapies which require daily use to manage symptoms, bronchial thermoplasty (three bronchoscopy sessions to treat all accessible airways) provides benefits and improvements in overall asthma control that are long lasting.
